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Bioinspired DNase-I-Coated Melanin-Like Nanospheres for
Modulation of Infection-Associated NETosis Dysregulation
Hee Ho Park, Wooram Park, Yun Young Lee, Hyelim Kim, Hee Seung Seo,
Dong Wook Choi, Ho-Keun Kwon, Dong Hee Na, Tae-Hyung Kim, Young Bin Choy,
June Hong Ahn,* Wonhwa Lee,* and Chun Gwon Park*
The current outbreak of the beta-coronavirus (beta-Cov) severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) began in December 2019.
No specific antiviral treatments or vaccines are currently available. A recent
study has reported that coronavirus disease 2019 (COVID-19), the disease
caused by SARS-CoV-2 infection, is associated with neutrophil-specific plasma
membrane rupture, and release excessive neutrophil extracellular traps
(NETs) and extracellular DNAs (eDNAs). This mechanism involves the
activation of NETosis, a neutrophil-specific programmed cell death, which is
believed to play a crucial role in COVID-19 pathogenesis. Further progression
of the disease can cause uncontrolled inflammation, leading to the initiation
of cytokine storms, acute respiratory distress syndrome (ARDS), and sepsis.
Herein, it is reported that DNase-I-coated melanin-like nanospheres (DNase-I
pMNSs) mitigate sepsis-associated NETosis dysregulation, thereby
preventing further progression of the disease. Recombinant DNase-I and
poly(ethylene glycol) (PEG) are used as coatings to promote the lengthy
circulation and dissolution of NET structure. The data indicate that the
application of bioinspired DNase-I pMNSs reduce neutrophil counts and
NETosis-related factors in the plasma of SARS-CoV-2 sepsis patients,
alleviates systemic inflammation, and attenuates mortality in a septic mouse
model. Altogether, the findings suggest that these nanoparticles have
potential applications in the treatment of SARS-CoV-2-related illnesses and
other beta-CoV-related diseases.
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1. Introduction
In recent decades, there have been recur-
rence of large-scale epidemics attributed to
coronaviruses such as severe acute respi-
ratory syndrome coronavirus (SARS-CoV),
Middle East respiratory syndrome coro-
navirus (MERS-CoV), and most recently,
SARS-CoV-2, which was discovered in pa-
tients with severe pneumonia in Decem-
ber, 2019.[1–3] CoVs are classified into four
categories, that is, alpha-CoV, beta-CoV,
gamma-CoV, and delta-CoV. Interestingly,
SARS-CoV, MERS-CoV, and SARS-CoV-2
are beta-CoV lineage viruses. Currently,
there are no specific antiviral treatments
or vaccines available for these beta-CoVs;
therefore, it is crucial to develop novel treat-
ment strategies to address the rapid spread
of this virus.
The full spectrum of coronavirus dis-
ease 2019 (COVID-19)—the disease asso-
ciated with SARS-CoV-2 infection—ranges
from mild respiratory tract illness to se-
vere progressive pneumonia, acute respira-
tory distress syndrome (ARDS), serum pro-
inflammatory cytokine elevation (cytokine
storm), multiple organ failure (MOF), and
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death.[1] SARS-CoV-2 infections are associated with both uncon-
trolled inflammatory innate immune responses and impaired
adaptive immune responses, leading to local and systemic tis-
sue damage.[4] The late stage of the disease is difficult to treat, as
the radical immune reactions propagate toward cytokine storms,
acute respiratory distress syndrome (ARDS), and septic shock,
leading to increased patient mortality.[5,6] The underlying mech-
anism as well as initiators that trigger and propagate the cy-
tokine storm, subsequently leading to the development of se-
vere COVID-19 are unknown.[4] A recent study has proposed that
neutrophilia might be linked to poor outcomes in patients with
severe COVID-19,[5] and it is believed to play a critical role in
COVID-19 pathogenesis.[7] NETosis, a special type of neutrophil-
specific programmed cell death, is a process in which reticu-
lar structures consisting of chromatin and granular proteins are
formed.[8,9] It has been suggested that excessive amount of NETo-
sis, which lead to a hyperinflammatory response,[10] is associated
with organ damage and MOF.[11] Hence, it is postulated that aber-
rant activation of neutrophils followed by release of neutrophil
extracellular traps (NETs) and extracellular DNAs (eDNAs) in the
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peripheral blood may contribute to organ damage and mortality
in sepsis-related diseases.[12] It is predicted that similar outcomes
may arise in COVID-19 patients.
Inspired by our observations and based on a recently published
report,[7] we suggest that the dissolution of a basic constituent
of NET structure—DNA—using DNase-I may be an appropriate
strategy for preventing NET-related pathogenesis in SARS-CoV-
2 patients. Previously, it had been demonstrated that the deliv-
ery of a recombinant DNase-I by inhalation led to the dissolu-
tion of NETs in the airways of cystic fibrosis (CF) patients, that
resulted in clear mucus and ameliorated symptoms.[13] In addi-
tion, the use of an actin-resistant DNase in CF patients in Phase
I and II clinical trials showed promising results (NCT02605590,
NCT02722122). When tested using animal models, delivery of
DNase-I through the airways resulted in increased survival,[14–16]
leading us to believe that DNase-I may help dissolve NETs
and prevent further progression to ARDS and sepsis in severe
COVID-19 patients. However, exogenously administered recom-
binant DNase-I showed only a modest effect, presumably due to
the short half-life of DNase-I in the blood plasma. Previous stud-
ies have reported that conjugation of DNase-I onto the surface of
nanoparticles enhances the stability and preserves the activity of
DNase-I in blood plasma.[17,18]
In this study, we report for the first time, demonstration
of DNase-I-coated melanin-like nanospheres (DNase-I pMNSs)
for modulation of sepsis-associated NETosis dysregulation.
Polydopamine-based DNase-I MNSs have a structure similar to
that of squid ink and skin melanin.[19–22] DNase-I was readily at-
tached to the nanoparticle surface through the excellent adhe-
sive properties of polydopamine.[23,24] Intravenous injection of
bioinspired DNase-I MNSs alleviated systemic inflammation and
attenuated mortality in a septic mouse model. We also show
that exogenously administered DNase-I MNSs exhibit a suppres-
sive effect against neutrophil activities, eDNA level, and cytokine
storm. Thus, our data support further investigation of DNase-I
MNSs as potential tools to treat SARS-CoV-2-mediated illnesses.
2. Results
2.1. Increased Neutrophil and Reduced Lymphocyte Counts
in Severe COVID-19 Patients
Computed tomography (CT) was performed, and blood samples
from COVID-19 patients were analyzed on their admission to
the hospital (Figure S1, Supporting Information, and Table 1).
CT imaging revealed that patients with severe clinical manifesta-
tions had severe lung tissue damage, indicating an increase in the
severity of septic symptoms (Figure S1, Supporting Information).
As reported previously, severe clinical manifestations such as
ARDS and sepsis, were mostly observed in elderly patients (mean
age 72.2 ± 13.1) who showed increased neutrophil counts and de-
creased lymphocyte counts when compared with the less severe
group (Table 1).[25,26] The later symptom lymphopenia is widely
recognized to be associated with the severity of diseases.[22]
2.2. Increased Levels of NETosis Markers in Severe COVID-19
Patients
Levels of extracellular DNA (eDNA), DNase-I and citrullinated
histone H3 (Cit-His H3) were measured in 20 healthy control
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Table 1. Laboratory findings of COVID-19 patients at the time of admission to hospital.
All patients (n = 60) Mild patients (n = 40) Severe patients (n = 20) p-Value
Characteristics
Age [y] 33.7 ± 16.4 55.4 ± 17.1 72.2 ± 13.1 0.014
ARDS 11 (18.3) 0 (0) 11 (55) <0.001
Sepsis 13 (21.7) 0 (0) 13 (65) <0.001
Discharged 40 40 (100) 0 (0) <0.001
Died 16 0 (0) 16 (80%) <0.001
Complete blood count
White blood cell count, × 109 L−1 [normal range 4–10] 6.5 ± 3.4 5.9 ± 3.6 9.1 ± 2.6 0.005
Neutrophil count, × 109 L−1 [normal range 3–7] 4.6 ± 3.4 4.1 ± 3.2 7.7 ± 3.3 <0.001
Lymphocyte count, × 109 L−1 [normal range 1.5–4] 1.4 ± 0.7 1.5 ± 0.7 0.8 ± 0.3 <0.001
Hemoglobin, g dL−1 [normal range 12–17] 13.0 ± 1.6 13.5 ± 1.7 13.0 ± 1.6 0.253
Platelets, × 109 L−1 [normal range 140–400] 237.3 ± 104.9 245.0 ± 107.9 186.7 ± 64.9 0.061
Data are presented as mean ± SD (range) or number (percentage). Mild patients: non-ICU, no symptom; severe patients: ICU, ventilator, oxygen treatment, ARDS, and sepsis.











eDNA [mg mL−1] 0.41 ± 0.12 0.85 ± 0.27 2.83 ± 0.37***
DNase-I [mg mL−1] 2.11 ± 0.38 3.11 ± 1.07 0.97 ± 0.30***
Cit-His H3 [mg mL−1] 0.05 ± 0.01 0.30 ± 0.32 17.74 ± 2.91***
Statistical analysis was performed using a two-tailed unpaired t-test. Data are pre-
sented as mean ± SEM. ***p < 0.001. eDNA, extracellular DNA; Cit-His H3, citrulli-
nated histone H3.
volunteers (normal group), and 60 blood samples from COVID-
19 patients, including mild patients and severe patients. The me-
dian serum eDNA level in the normal group was 0.41 (0.29–0.53)
µg mL−1. In comparison, the level of eDNA was slightly increased
to 0.85 (0.58–1.12 µg mL−1) in the 40 mild COVID-19 patients and
drastically increased to 2.83 (2.46–3.20) µg mL−1 in the 20 severe
COVID-19 patients (Table 2). The median serum Cit-His H3 lev-
els in the blood samples showed much more drastic differences.
In the normal group, the Cit-His H3 median level was slightly
increased from 0.05 (0.04–0.06) µg mL−1 to 0.30 (0.02–0.62)
µg mL−1 in mild COVID-19 patients, and significantly increased
to 17.74 (14.83–20.65) µg mL−1 in severe COVID-19 patients. A
slightly different effect was observed for DNase-I, that is, in the
normal group, the median DNase-I level was slightly increased
from 2.11 (1.73–2.49) µg mL−1 to 3.11 (2.04–4.18) µg mL−1 in
the mild COVID-19 patients, but decreased to 0.97 (0.67–1.27)
µg mL−1 in severe COVID-19 patients.
2.3. Preparation and Characterization of DNase-I pMNSs
The bare bioinspired melanin-like nanospheres (bMNSs) were
surface-modified with DNase-I to improve the stability and thus
activity of DNase-I (Figure 1a).[27] The melanin-like nanoparti-
cles were synthesized through oxidation of dopamine based on
the protocol published in our previous paper.[21] Then, DNase-
I and PEG were immobilized on the surface of nanoparticles
in a one-pot process. The particle sizes of bMNSs, pMNSs, and
DNase-I pMNSs were similar, approximately 170 nm (Figure 1b).
The surface charge of bMNSs was measured to be −12.4 mV,
which neutralized to −0.15 mV when the PEG coating was intro-
duced to generate pMNSs (Figure 1c). The surface of the DNase-I
pMNSs was negatively charged (−10.9 mV) due to coating with
DNase-I. Data also confirmed the spherical appearance and rel-
atively monodispersed size of the nanoformulations (Figure 1d).
The DNA degradation capability of DNase-I pMNSs was evalu-
ated using agarose gel electrophoresis (Figure 1e). Free DNase-I
(1 U) completely degraded 1 µg DNA. pMNSs and bMNSs did
not degrade DNA due to the absence of DNase-I on their sur-
face. However, DNase-I pMNSs degraded DNA at a concentration
> 1.0 µg of nanospheres, suggesting that the effect was due to the
activity of coated DNase-I on pMNSs. To evaluate the amount of
DNase-I that can be bound to pMNSs, nanoparticles were pre-
pared with various ratios of pMNSs and DNase-I. The binding
contents and binding efficiency of DNase-I on pMNSs were mea-
sured through BCA assay (Table S1, Supporting Information).
As the feed amount of DNase-I increased, the actual amount of
DNase-I binding to the nanoparticles increased, but the binding
efficiency of DNase-I was limited to less than 83%. However, the
DNase-I pMNSs3 containing ≈45% of DNase-I showed excellent
stability and DNA degradation properties, thus DNase-I pMNSs3
was selected and used in further experiments. Then, to analyze
the binding stability of nanoparticles and DNase-I, the activity of
DNase-I over time in PBS containing 10% FBS or PBS only me-
dia, was tested. When DNase activity was tested after incubation
of long-acting DNase-I in media containing 10% FBS for 72 h
(Figure S2(a), Supporting Information), the activity of DNase-I
pMNSs was maintained for up to 36 h, but the activity decreased
after 48 h. However, in PBS only media (Figure S2(b), Supporting
Information), the activity of DNase-I pMNSs was maintained for
up to 72 h.
2.4. Exogenous DNase-I pMNSs Alleviated NETosis Factors in
the Plasma and Neutrophils of Severe COVID-19 Patients
After observing an increase in the levels of NETosis-related fac-
tors, we hypothesized the necessity to compensate for the loss
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Figure 1. Physicochemical characterization of pMNSs. a) Preparation of DNase-I pMNSs. b) Size distribution of bMNSs, pMNSs, and DNase-I pMNSs.
c) Zeta potentials of bMNSs, pMNSs, and DNase-I pMNSs. d) Scanning electron microscopy (SEM) images of bMNSs, pMNSs, and DNase-I pMNSs
(scale bar: 500 nm). e) Migration profile of pure DNA after digestion with free DNase-I, pMNSs, and bMNSs, as well as various amounts of DNase-I
pMNSs. pMNSs, PEG-coated melanin-like nanospheres; bMNSs, bare bioinspired melanin-like nanospheres.
of endogenous DNase-I in severe COVID-19 patients. We there-
fore validated the effects of DNase-I pMNSs on reduction of the
neutrophils in NETosis. To demonstrate the effects of DNase-I
on DNA degradation, we treated the plasma of severe COVID-
19 patients with either free DNase-I or DNase-I pMNSs. The re-
sults showed that both forms of DNase-I significantly reduced
the eDNA levels (Figure 2a), and that exposure of DNase-I to
the plasma of severe COVID-19 patients increased the activ-
ity of DNase-I (Figure 2b). We also observed markedly reduced
NET levels, MPO activity, and NE levels in neutrophils of severe
COVID-19 patients upon treatment with DNase-I pMNSs (Fig-
ure 2c–e).
As shown in Table 1, over 50% of the severe COVID-19 patients
were diagnosed with ARDS and sepsis on admission to the hos-
pital. Typically, sepsis is accompanied by a cytokine storm,[4] a
deadly uncontrollable systemic inflammatory response resulting
from the burst of vast amounts of pro-inflammatory cytokines
by immune effector cells.[28] Therefore, we evaluated the effects
of DNase-I pMNSs on NF-𝜅B activation and cytokine secretion
from neutrophils. The results showed that the activity of NF-𝜅B
and secretion of cytokines IL-1𝛽, IL-6, IFN-𝛾 , and TNF-𝛼 were
slightly reduced upon treatment with free DNase-I, and were fur-
ther drastically reduced upon treatment with DNase-I pMNSs
(Figure 2f–j).
2.5. DNase-I pMNSs Alleviated NETosis Factors in a Septic
Mouse Model
After confirming reduction in neutrophil counts and neutrophil-
related NETosis factors in severe COVID-19 patients upon treat-
ment with DNase-I MNSs in vitro, we further validated the ef-
fects of DNase-I pMNSs in vivo. Based on a recent report that
neutrophil activity is a valid target for preventing or reducing
sepsis and enhancing survival,[7] we tested the exogenous ad-
ministration of the DNase-I pMNSs in an in vivo setting: cecal
ligation and perforation (CLP)-treated septic mouse model (Fig-
ure 3a). CLP mouse model is the most frequently used model to
investigate the complex molecular mechanisms of sepsis.[29] Sep-
sis is induced via polymicrobial infectious focus within the ab-
dominal cavity, followed by bacterial translocation into the blood
compartment, which triggers a systemic inflammatory response.
Similar phenotypes are observed in the CLP model, and severe
COVID-19 patients; NETosis, cytokine release syndrome (CRS),
and multiple organ failure (MOF) syndrome can be induced in
the CLP model. Hence, the CLP model can be used to represent
the SARS-CoV-2-induced severe COVID-19 patients. The CLP
model was considered an appropriate in vivo model for the cur-
rent setting due to the absence of available alternatives. To con-
firm the anti-NETosis effects of DNase-I pMNSs, CLP-operated
mice were intravenously injected with phosphate-buffered saline
(PBS; control group), PEG-Nano, free DNase-I (100 units), or
DNase-I pMNSs (100 units) at 12 h and 24 h post-CLP-operation.
We measured the DNase-I activity 24 h after drug administration
(48 h post-CLP-operation); Colón et al. measured the activity af-
ter 18 h,[30] Yoshikawa et al. measured the activity after 24 and
48 h NET,[31] and Czaikoski et al. measured the activity at 48 h.[11]
Previously, it was reported that neutrophil activity increases af-
ter CLP surgery as a function of time.[32] To effectively suppress
the rapidly increasing NET, the drug was administered at 12 and
24 h and the effect was confirmed 24 h after drug administration
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Figure 2. DNase-I pMNSs suppress NETosis factors and cytokine storm via down-regulation of NF-𝜅B activation. a) eDNA and b) DNase-I levels in
the plasma of severe COVID-19 patients, as well as c) NET, d) MPO, and e) NE levels in neutrophils isolated from severe COVID-19 patients. Plasma
and neutrophil samples were collected from 20 severe COVID-19 patients. f) Suppression of NF-𝜅B activation in severe COVID-19 patients’ PBMCs
after the treatment of free-DNase-I or DNase-I pMNSs. g–j) Reduction of secreted cytokine levels, including g) IL-1𝛽, h) IL-6, i) IFN-𝛾 , and j) TNF-
𝛼 in severe COVID-19 patients’ PBMCs after the treatment of free-DNase-I or DNase-I pMNSs. Statistical analysis was performed using a two-tailed
unpaired t-test. Data are presented as mean ± SEM. *p < 0.05, **p < 0.01. pMNSs, PEG-coated melanin-like nanospheres; eDNA: Extracellular DNAs;
NET, Neutrophil extracellular trap; MPO, Myeloperoxidase; NE, Neutrophil elastase; PBMC, Peripheral blood mononuclear cells; NF-kB, Nuclear factor
kappa-light-chain-enhancer of activated B cells; IL-1𝛽, Interleukin-1 beta; IL-6, Interleukin-6; IFN- 𝛾 , Interferon-𝛾 ; TNF-𝛼, tumor necrosis factor-𝛼.
(48 h post-CLP-operation). All of the CLP-operated mice died
within 90 h of CLP induction when PBS, PEG-Nano, or free
DNase-I were administered. This demonstrated the high mortal-
ity rate of the CLP-operated sepsis model. Previously, the phar-
macodynamics of recombinant human DNase-I in the serum was
analyzed, indicating a short half-life,[33] and a lack of in vivo ef-
fect of free DNase-I. Interestingly, DNase-I pMNSs demonstrated
a 40% survival rate for the CLP-operated septic mice for over 132
h, leading to the full recovery of these mice. We then confirmed
the effect of DNase-I pMNSs on the lungs, and we found a sig-
nificant reduction in the morphological changes caused by CLP,
including pulmonary edema, hemorrhage, alveolar collapse, and
inflammatory cell infiltration (Figure 3b).
To further evaluate the efficacy of DNase-I pMNS treatment
in a therapeutic setting, we evaluated the levels of neutrophils,
NETs, eDNA, DNase activity, NE activity, and MPO activity in
the intraperitoneal cavity of CLP-operated mice (Figure 3c–h).
In agreement with the effects observed in the plasma and neu-
trophils of severe COVID-19 patients (Figure 2), similar results
were observed in which DNase-I pMNSs induced a drastic re-
duction in the levels of peritoneal neutrophils, NETs, eDNA,
NE activity, and MPO activity compared to those in the con-
trol group (PBS treatment) and free DNase-I group. It was also
clearly demonstrated that DNase activity increased dramatically
in DNase-I pMNSs group, compared to the control group (PBS
treatment).
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Figure 3. Anti-NETosis effects of DNase-I pMNSs in the sepsis mouse model. Male C57BL/6 mice (n = 60/group pooled from 3 independent experi-
ments) were administered PBS, PEG-Nano (100 units), free DNase-I (100 units), or DNase-I pMNSs (100 units) 12 h and 24 h after CLP, and the blood
was withdrawn and measured 24 h later (48 h post-CLP-operation). a) Kaplan-Meier curves of CLP mice administered PBS, PEG-Nano (100 units), free
DNase-I (100 units), or DNase-I pMNSs (100 units). b) Histological changes in the lung 3 d after CLP treatment. Representative images from each
group are shown (n = 5). Scale bar, 100 µm. c) Neutrophils, d) NETs, e) eDNA, f) DNase-I activity, g) NE activity, and h) MPO activity were measured.
Representative data from each group are shown (n = 5). The experiment was performed at least three times with replicates. Statistical analysis was
performed using a two-tailed unpaired t-test. *p < 0.05, **p < 0.01. pMNSs: PEG-coated melanin-like nanospheres; CLP, Cecal ligation and perforation;
PBS, Phosphate buffered saline; NETs, Neutrophil extracellular traps; eDNA: Extracellular DNAs; NE, Neutrophil elastase; MPO, Myeloperoxidase.
Next, we evaluated the effect of the DNase-I pMNSs on the
regulation of inflammatory responses in the CLP-operated sepsis
model. As mentioned before, systemic inflammation associated
with sepsis often causes MOF syndrome,[34] and it has been re-
ported that the major organ targets of MOF syndrome are the kid-
ney and liver.[35] CLP treatment significantly increased the serum
levels of hepatic injury markers alanine transferase (ALT) and as-
partate transaminase (AST) (Figure S3a and b, Supporting In-
formation), renal injury markers blood urea nitrogen (BUN) and
creatinine (Figure S3c–d, Supporting Information), tissue injury
marker lactate dehydrogenase (LDH) (Figure S3e, Supporting In-
formation), and pneumonia and sepsis marker C-reactive pro-
tein (CRP) (Figure S3f, Supporting Information). Treatment with
DNase-I pMNSs led to apparent reductions in the serum levels of
all these markers.
We also evaluated the absolute number of neutrophils, leuko-
cytes, and total white blood cells (WBCs) in the blood of the
CLP-operated sepsis model (Figure S4a–c, Supporting Informa-
tion). Similar to the effect shown in the intraperitoneal cavity of
CLP-operated sepsis model (Figure 3c), DNase-I pMNSs caused
a drastic reduction in the number of neutrophils and the total
number of WBCs in the blood relative to those observed in the
control group (PBS treatment) (Figure S4a and c, Supporting In-
formation). However, compared to the control group (PBS treat-
ment), no difference was observed in the number of leukocytes
in the blood (Figure S4b, Supporting Information). Cytokine ar-
ray analysis on lung tissue in the CLP-operated mouse model
revealed the upregulation of inflammatory cytokines (Figure 4).
The upregulated cytokines included IL-6, IL-8, IL-1𝛽, CCL2, etc.
The high level of cytokines observed in the lung tissue in the
CLP-operated mouse model supports the sudden rise in the sys-
temic inflammatory response, including the triggering of the “cy-
tokine storm” after SARS-CoV-2 infection. However, upon treat-
ment with DNase-I pMNSs, the level of cytokines such as IL-
6, IL-8, IL-1𝛽, and CCL2, was significantly reduced in the lung
tissue samples. As SARS-CoV-2 causes damage to vascular en-
dothelial cells and induces severe lung damage, we evaluated
whether DNase-I can protect vascular barrier disruption by ob-
serving the transendothelial permeability in the septic mouse
model (Figure S5, Supporting Information). As a result, free
DNase-I was only effective initially and the effect disappeared af-
ter 72 h upon administration, but in the group administered with
DNase-I pMNSs, the survival rate was maintained even after 72 h.
The observed features in the blood of animal models support the
improved outcomes after the DNase-I pMNSs administration. To
verify whether the ability of the nanoparticle-bound is DNase-I
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Figure 4. Cytokine levels in the lung tissue in CLP-operated mouse model. Heat map of inflammation-related genes in the lung tissue after DNase-I
pMNSs treatment (n = 3). CLP, Cecal ligation and perforation; pMNSs: PEG-coated melanin-like nanospheres.
concentration dependent, we generated various concentrations
of DNase-I pMNSs, and observed concentration-dependent sur-
vival rate in vivo (i.e., DNase-I as variable and nanoparticles
as constant; 25, 50, and 100 units) (Figure S6, Supporting
Information).
3. Discussion
NETosis, a neutrophil-specific oxidative explosion-dependent
process, leads to the release of neutrophil extracellular traps
(NETs).[10] NETosis is a special type of programmed cell death
in which reticular structures consisting of a DNA backbone and
a number of functional proteins are formed. Initially, the neu-
trophil elastase (NE) degrades the core histone protein and the
linker H1 histone protein, resulting in neutrophil nuclei losing
their characteristic shape. Then, a combination of nuclear rup-
ture and granular membranes leads to chromatin decondensa-
tion and the release of NETs into the extracellular space, en-
hanced by myeloperoxidase (MPO). These NETs correspond to
extracellular filaments of uncondensed chromatin coated by nu-
merous granular proteins. During this process, Cit-His H3 is
thought to be involved in the formation of NETs. NETs have been
linked to severe infections such as sepsis, in which the release of
chromatin with neutrophil granular proteins serves as an addi-
tional defense of the innate immune system against circulating
microbes, including bacteria, fungi, protozoa, and viruses. Re-
cently, Zuo et al. verified that sera from patients with COVID-19
have elevated levels of cell-free DNA (eDNA), myeloperoxidase-
DNA (MPO-DNA), and citrullinated histone H3 (cit-His H3), and
demonstrated that the latter two (MPO and cit-His H3) are spe-
cific markers of NETs.[36] In patients with severe COVID-19, lym-
phopenia has been observed as a collective and representative
characteristic, accompanied by an increased ratio of neutrophils
as well as an increase in the absolute neutrophil count.[25,26] In ad-
dition, a recent study has proposed that NETosis is perhaps linked
to poor outcomes in patients with COVID-19 and is believed to
play a crucial role in COVID-19 pathogenesis.[7] It is postulated
that aberrant activation of neutrophils, an increase in the release
of NETs, and eDNAs in peripheral blood may contribute to organ
damage and mortality in COVID-19 patients.
A recently published report[7] and in our own independent
work have demonstrated elevated levels of NETosis markers,
such as eDNA, MPO and NE.[10,37,38] These are characteristic
features of critically ill patients with COVID-19.[39] Hence, we
hypothesized that DNase-I could be used to ameliorate the disso-
lution of the main constituent of NET structure, DNA, and thus
prevent NET-related pathogenesis, including progression toward
ARDS and sepsis in severe COVID-19 patients. However, it is
quite challenging to treat patients with high levels of NETosis,
and it is linked with high mortality and morbidity rates. There-
fore, a novel NETosis-targeting agent able to tackle and reduce
NETosis in the blood is essential to prevent further progression
toward sepsis. Currently, there are no FDA-approved drugs to
treat severe COVID-19. Existing antivirals and antimalarials that
are being used in clinical trials for the treatment of SARS-CoV-2
have shown therapeutic efficacy in only patients with mild
conditions and not in severe COVID-19 patients with ARDS or
sepsis. Remdesivir has shown some promising results in mild
COVID-19 patients; however, it is still an investigational antiviral
drug and is not currently FDA-approved to treat or prevent any
diseases, including COVID-19. This highlights the urgent need
for an alternative means of treating severe COVID-19 patients
by effectively suppressing the inflammation-mediated MOF
syndrome.
Although degrading the NET structure could serve as
a promising strategy to suppress NET-related complications
in COVID-19 patients, it has been reported that the half-
life of DNase-I in the blood is very short.[33] Previously, a
polydopamine-coated polymeric nanoparticle was proposed as
a long-acting DNase-I formulation.[17,18] In this study we re-
port, we demonstrated DNase-I-coated melanin-like nanospheres
(DNase-I pMNSs) for the amelioration of sepsis-associated NETo-
sis (Figure 1). The DNase-I pMNSs possess a structure similar to
that of squid ink and skin melanin.[19–22] As melanin nanoparti-
cles using polydopamine are processed in water without using
organic solvents, the synthesis of melanin nanoparticles is envi-
ronmentally friendly. In addition, the excellent adhesion prop-
erties of polydopamine enable the effective immobilization of
the biomolecules on the surface of nanoparticles, thereby en-
abling various bioapplications. The interaction between the sur-
face of melanin nanoparticles and DNase-I is Michael addition or
Schiff base reaction between the catechol group of melanin and
the amine group of DNase-I.[40,41] We observed that the DNase-I
pMNSs maintained their activity in a biologically relevant solu-
tion (media containing FBS) for 36 h (Figure S2, Supporting In-
formation). This is thought to be because the DNase-I attached on
the nanoparticle surface could leech off or exchange in the pres-
ence of FBS. Nonetheless, it is assumed that the 36 h-stability of
the nanoparticles is sufficient even under the biological settings
(during circulation in the blood containing human serum albu-
min) after injection.
We also performed a comparative study using blood samples
from severe COVID-19 patients and demonstrated the suppres-
sion of NETosis factors such as eDNA, NET, MPO, NE, and
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cytokine levels (Figure 2). Through the administration of exoge-
nous DNase-I pMNSs in the CLP-operated septic mouse model,
we demonstrated that DNase-I pMNSs effectively reduce sepsis-
associated NETosis factors (Figures 3 and 4). We also showed
that administration of the DNase-I pMNSs significantly reduces
NETosis factors such as eDNA, NET, MPO, and NE in the CLP-
operated septic mice (Figure 3). These observations are also
consistent with cytokine array analysis in lung tissue from the
CLP-operated mouse model, which revealed that DNase-I pMNS
treatment lead to a reduction in the level of sepsis-related pro-
inflammatory cytokines, such as IL-6, IL-8, IL-1𝛽, and CCL2 (Fig-
ure 4). In particular, intravenous injection of DNase-I pMNSs al-
leviated the systemic inflammation and attenuated mortality in a
septic mouse model, resulting in a 40% survival rate for the CLP-
operated septic mice at 132 h post-induction (Figure 3a), demon-
strating that the mice had fully recovered. The free DNase-I is
effective at the beginning of administration (Figure 3f), but in
the group administered with DNase-I pMNSs, it was confirmed
that the effect lasted until 72 h and improved the survival rate
(Figure 3a). The free DNase-I is effective up to about 24 h after
administration, and the DNase-I-bound nanoparticles (DNase-I
pMNSs) acted longer and improved the mortality (Figure 3a).
These results indicate that early administration of the DNase-
I pMNSs during the early phase of sepsis may slow progres-
sion toward ARDS and sepsis, thereby potentially treating the
symptoms in severe COVID-19 patients. Our data support fur-
ther investigation of DNase-I pMNSs for the treatment of severe
COVID-19-mediated illnesses. Although the suggestion to use
DNase-I pMNSs as a potential treatment for severe COVID-19
is based entirely on in vitro blood samples derived from severe
COVID-19 patients and in vivo studies using the CLP-operated
septic mouse model as a surrogate for SARS-CoV-2 infection,
our results demonstrate that NETosis factor, cytokine release, and
lung damage were significantly alleviated after treatment. In ad-
dition, sepsis-associated inflammatory response including, NF-
𝜅B activation were inhibited upon the administration of DNase-I
pMNSs. It is worth noting that the efficacy of DNase-I pMNSs
needs to be further validated in an appropriate in vivo setting us-
ing an ARDS- or sepsis-inducing infection animal model before
moving forward to clinical trials on patients with COVID-19.
4. Conclusion
Based on our data from severe COVID-19 patients, we demon-
strated that eDNA, a NETosis factor, is a potential target for the
treatment of SARS-CoV-2-induced sepsis. We suggest therapeu-
tic delivery of a DNase-I pMNSs for the suppression of eDNA,
thereby alleviating the progression of sepsis in severe COVID-19
patients. We confirmed the effectiveness of the DNase-I pMNSs
in blood samples collected from actual COVID-19 patients as well
as in a CLP-operated septic mouse model. DNase-I pMNSs is a
promising bioinspired vehicle and demonstrates a potential new
strategy for SARS-CoV-2-induced sepsis therapy. There are cur-
rently no other reports that target the NETosis factor for the treat-
ment of severe COVID-19 patients. Recently, DNase-I was deliv-
ered to dissolve NETs in patients with CF, and our findings impli-
cate DNase-I pMNSs as a suitable material for clinical translation
and for preventing the progression of sepsis in severe COVID-19
patients. Our findings indicate the possibility of using NETosis
factors as diagnostic targets in severe COVID-19 patients.
5. Experimental Section
Materials: Dopamine hydrochloride and poly(ethylene glycol) (PEG,
four arm-amine termini, HCl salt) were obtained from Sigma (PA, USA)
and JenKem (TX, USA), respectively). NaOH solution (1 N) and Tris buffer
(10 mM, pH 8.5) were purchased from Daejung (Suwon, Korea) and
Biosesang (Seoul, Korea), respectively. Recombinant DNase-I was pur-
chased from Roche (Basel, Switzerland). Pierce BCA Protein assay kit was
from Thermo Scientific (MA, USA). Dulbecco’s phosphate-buffered saline
(PBS), and fetal bovine serum (FBS) were from Welgene (Gyeongsan, Ko-
rea) and Gibco (CA, USA), respectively.
Plasma Samples: At Yeungnam University Medical Center, whole
blood samples were collected from patients after they were diagnosed
with the SARS-CoV-2 infection at a public health center in Daegu, Repub-
lic of Korea. Patients with COVID-19 sepsis were defined using criteria
provided by the Sepsis Consensus Conference Committee.[42] The human
study protocol was approved by the Institutional Review Board of Yeung-
nam University Hospital at Daegu in Korea (YUH 2020-03-057, 2020-05-
031-001).
Neutrophil Counts of Patients with COVID-19: Complete blood counts
were analyzed in venous blood samples within 24 h of the admission of
patients in the hospital. Neutrophil count was analyzed using a Sysmex
XE-2100 Automated Hematology System (TOA Medical Electronics, Kobe,
Japan).
NET Enzyme-Linked Immunosorbent Assay (ELISA): NETs were gener-
ated from freshly isolated neutrophils (1 × 105 cells) by stimulating the
cells with phorbol-myristate acetate (25 nM) (PMA, Sigma-Aldrich, MO,
USA) or control media (RPMI 1640 supplemented with glutamine, peni-
cillin, and streptomycin) and analyzed using a fluorometric technique as
previously described.[43] NET production was measured as arbitrary fluo-
rescent units (AFUs).
MPO ELISA: Plasma samples were analyzed to quantify the release of
granule matrix proteins upon degranulation in peripheral blood mononu-
clear cells (PBMCs) of SARS-CoV-2-infected patients and mice, using a
human MPO ELISA kit (BMS2038INST, Invitrogen) and mouse myeloper-
oxidase ELISA kit (MBS700747, MyBioSource), respectively.
Cit-His H3 ELISA: Cit-His H3 concentration in cell culture media or
SARS-CoV-2 patient sera was determined using a human citrullinated his-
tone H3 ELISA Kit (MBS7254090, MyBioSource).
Quantification of Plasma Extracellular DNA (eDNA): To quantify eDNA
from the plasma of SARS-CoV-2-infected patients or mouse plasma,
plasma samples were centrifuged at 16800× g for 10 min and DNA was ex-
tracted using a Qiagen QIAamp DNA Mini Blood Mini Kit according to the
manufacturer’s protocols (Qiagen, Valencia, CA, USA) The purified eDNA
was quantified using a NanoDrop spectrophotometer.
ELISA for DNase-I Activity: Plasma samples were diluted 1:50 and
analyzed using digestion buffer spiked with double-stranded DNA
(1 µg mL−1). Samples were stained with PicoGreen (Invitrogen) according
to the manufacturer’s protocol. After incubation at 37 °C for 5 h, reduction
in PicoGreen staining (fluorescence emission, Em) was then measured
using a fluorometer.
Preparation of DNase-I pMNSs: Bare melanin-like nanospheres
(bMNSs) were synthesized by dopamine hydrochloride, as presented in
our previous report[21] (Figure 1). Dopamine hydrochloride (10 mg) was
dissolved in deionized water (DW, 50 mL). Then, NaOH solution (50 µL, 1
N) was added to the dopamine hydrochloride solution. The reaction was
stirred for 24 h, and the color gradually changed to black as the reaction
proceeded. For purification, the prepared bMNSs were collected via cen-
trifugation at 17 000 rpm (27237 × g-force) for 20 min and washed with
deionized water (DW) three times. To prepare DNase-I pMNSs, surface
engineering of bMNSs with DNase-I was performed according to our pre-
vious reports.[17,18] The resulting bMNSs (10 mg) were re-suspended in
Tris buffer (5 mL, 10 mM, pH 8.5) containing DNase-I (2, 5, 10, or 20 mg)
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and poly(ethylene glycol) (10 mg, PEG, four arm-amine termini, HCL salt),
and stirred at 4 °C for 3 h. The prepared DNase-I pMNSs were purified
in the same manner as above and washed with DW multiple times. We
also prepared PEG-coated MNSs (pMNSs) as a control, using the same
method as for DNase-I pMNSs, but without DNase-I addition.
Characterization of MNS: The particle size and surface charge of
nanospheres were measured by dynamic light scattering (DLS: Malvern
Instruments, Southborough, Massachusetts). The morphology of the
nanospheres was observed by field emission scanning electron mi-
croscopy (FE-SEM: JEM-7500F, Akishima, Japan). The enzymatic activity
of DNase-I pMNSs was confirmed via degradation of highly polymerized
salmon sperm DNA (Sigma-Aldrich, PA, USA) by gel electrophoresis.[18]
For this, bMNSs, pMNSs, or DNase-I pMNSs were incubated with 1 µg of
salmon sperm DNA for 10 min at 37 °C, followed by gel electrophoresis.
Neutrophil Isolation: For density gradient isolation of PBMCs, Percoll
(pH 8.5–9.5; Sigma-Aldrich, UK) was used as previously described.[44] The
PBMCs (95% purity and 97% viable according to trypan blue exclusion)
were resuspended in RPMI 1640 media (Sigma-Aldrich). For discontin-
uous density gradient centrifugation of neutrophils, 1-step Polymorphs
(Axis-Shield, Oslo, Norway) were used. To further increase the purity, the
neutrophil population was purified using CD45 antibody-conjugated mag-
netic beads and magnetic-activated cell sorting (MACS). Trypan blue dye
exclusion showed that the general viability of the neutrophils was >95%.
To analyze the effect of DNase-I on inhibition of cytokine production, neu-
trophils were isolated from COVID-19 patients and treated with DNase-I
MNSs. DNase-I MNSs were also administrated to CLP-operated septic
mice. Supernatants were used for cytokine assay using ELISA, and cell
lysates were used for analysis of NF-kB activity.
NF-𝜅B Activity: Nuclear extracts were prepared, and TransAM assays
were performed as previously described.[45] The activity of individual NF-
𝜅B subunits was determined via ELISA using NF-𝜅B Family Transcription
Factor Assay Kit (43296; Active Motif, Carlsbad, CA, USA). Briefly, nuclear
extracts (2 µg) were placed into wells of NF-𝜅B consensus oligonucleotide-
coated 96-well plates. Plates were incubated with NF-𝜅B primary antibody,
and then binding was detected using HRP-conjugated secondary antibody
included with the kit. For analysis, the optical density (OD) at 450 nm was
measured using a Tecan Spark microplate reader (Tecan, Austria GmbH,
Austria).
Cytokine ELISAs: Levels of inflammatory cytokines IL-1b, IL-6, IFN-
g, and TNF-𝛼 in the supernatant were measured after treating PBMCs
with pMNSs, Free-DNase-I, and pMNSs-DNase-I (100 unit) using human
ELISA kits (Quantikine ELISA, R&D Systems, Minneapolis, MN, USA) ac-
cording to the manufacturer’s protocols.
Animals: Animal experiments were carried out in accordance with pro-
tocols approved by the Institutional Animal Care and Use Committee
(IACUC) of Sungkyunkwan University College of Medicine (IACUC No. No.
SKKU IACUC2020-06-29-2). Six- to seven-week-old C57BL/6 male mice
(18–20 g) were obtained from Orient Bio (Seongnam, Korea). Mice were
used after a 12-day acclimatization period. Five animals per cage were
housed under controlled temperature at 20–25 °C and humidity of 40–
45% with a 12:12 h light/dark cycle. Mice were fed a normal rodent pellet
diet and supplied with water ad libitum.
Cecal Ligation and Puncture: The CLP-operated septic mouse model
was prepared as previously described.[29] Briefly, a 2-cm midline incision
was made to expose the cecum and adjoining intestine. The cecum was
then ligated tightly using a 3.0-silk suture 5.0 mm from the cecal tip, punc-
tured with a 22-gauge needle, and then gently squeezed to extrude feces
from the perforation site. The cecum was then returned to the peritoneal
cavity, and the laparotomy site was sutured using 4.0-silk. For sham op-
erations, the cecum of animals was surgically exposed, but not ligated or
punctured, and then returned to the abdominal cavity.
In Vivo Neutrophil Migration Assays: To assess neutrophil migration,
CLP-operated mice were treated with pMNSs, free DNase-I, and pMNSs-
DNase-I (100 units) 6 h after CLP surgery. Mice were then euthanized,
and the peritoneal cavities were washed with 5 mL of normal saline.
Neutrophils were counted using an auto hematology analyzer (Mindray,
BC-5000 Vet). Results are expressed as neutrophils × 106 per peritoneal
cavity.
RNA Analysis: RNA from lung tissue was extracted using an RNeasy
mini-kit (Qiagen Venlo, Netherlands) according to the manufacturer’s pro-
tocols. RNA-seq libraries were prepared using the TruSeq RNA Sample
Prep kit v2 (Illumina) according to the manufacturer’s protocols. RNA-seq
libraries were pair-end sequenced on an Illumina Hi-seq 3000/4000 SBS kit
v3 (MACROGEN Inc.). All RNA-seq data were mapped using the Tophat
package[46] against Affymetrix Human Gene 2.0 ST arrays (902136). Re-
maining mRNA was used for qPCR analysis. Fold-change was determined
using the R package limma, and P-values were Benjamini-Hochberg (BH)
adjusted. The array results are available in the Gene Expression Omnibus
(GEO) database of NCBI (Accession code: GSE101126).
Hematoxylin and Eosin (H&E) Staining and Histopathological Examina-
tion: Male C57BL/6 mice were CLP-operated and then intravenously ad-
ministered pMNSs, free DNase-I, or DNase-I pMNSs (100 units) at 12 h or
24 h after CLP (n = 5). At 72 h post-CLP operation, mice were euthanized.
Lung specimens were removed from mice for the analysis of phenotypic
changes. H&E staining was performed using a standard protocol.
Cytokine Levels in the Plasma of Septic Mice: Fresh serum was used for
analysis of AST, ALT, BUN, creatinine, and LDH levels using biochemical
kits (MyBioSource). Values were measured using an ELISA plate reader
(Tecan, Austria GmbH, Austria).
Statistical Analysis: All the in vitro and in vivo data were analyzed via
two-tailed unpaired t-test using the Graphpad prism 7 software, the pre-
pared sample sizes were n ≥ 3, and the statistical significance was set at P
<0.05. A more detailed information for each experiment is provided in the
Figure legend. All data normalization processes were carried out accord-
ing to the manufacturer’s protocol. Data transformation and evaluation of
outliers were not used in our study.
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